ALPHAMAB-B Reports Annual Loss of RMB 114 Million, Shifting from Profit Year-on-Year

Stock News

Mar 25

ALPHAMAB-B (09966) announced its annual results for the period ending December 31, 2025. The company recorded revenue of RMB 566 million, representing a decrease of 11.54% compared to the previous year. It reported an annual loss of RMB 114 million, a shift from profit to loss year-on-year. The loss per share was RMB 0.12. According to the announcement, research and development expenses increased from RMB 404 million for the year ended December 31, 2024, to RMB 572 million for the year ended December 31, 2025. This increase was primarily attributable to (i) a rise in the number of ongoing clinical trials; (ii) the expansion of the scale of the company's clinical studies; and (iii) progress in clinical trials for the company's drug candidates. A detailed breakdown of R&D expenses by nature for the indicated years is provided in the table below.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1148962410"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148962410\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148962410?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 23:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148962410","market":"fut","top_or_hot":-1,"title":"ALPHAMAB-B Reports Annual Loss of RMB 114 Million, Shifting from Profit Year-on-Year","media":"Stock News","content":"<p>ALPHAMAB-B (09966) announced its annual results for the period ending December 31, 2025. The company recorded revenue of RMB 566 million, representing a decrease of 11.54% compared to the previous year. It reported an annual loss of RMB 114 million, a shift from profit to loss year-on-year. The loss per share was RMB 0.12. According to the announcement, research and development expenses increased from RMB 404 million for the year ended December 31, 2024, to RMB 572 million for the year ended December 31, 2025. This increase was primarily attributable to (i) a rise in the number of ongoing clinical trials; (ii) the expansion of the scale of the company's clinical studies; and (iii) progress in clinical trials for the company's drug candidates. A detailed breakdown of R&D expenses by nature for the indicated years is provided in the table below.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALPHAMAB-B Reports Annual Loss of RMB 114 Million, Shifting from Profit Year-on-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALPHAMAB-B Reports Annual Loss of RMB 114 Million, Shifting from Profit Year-on-Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-25 23:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ALPHAMAB-B (09966) announced its annual results for the period ending December 31, 2025. The company recorded revenue of RMB 566 million, representing a decrease of 11.54% compared to the previous year. It reported an annual loss of RMB 114 million, a shift from profit to loss year-on-year. The loss per share was RMB 0.12. According to the announcement, research and development expenses increased from RMB 404 million for the year ended December 31, 2024, to RMB 572 million for the year ended December 31, 2025. This increase was primarily attributable to (i) a rise in the number of ongoing clinical trials; (ii) the expansion of the scale of the company's clinical studies; and (iii) progress in clinical trials for the company's drug candidates. A detailed breakdown of R&D expenses by nature for the indicated years is provided in the table below.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYB","symbol_name":"人民币ETF-WisdomTree Dreyfus","start_time":0,"source_url":"","article_id":"1148962410","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148962410","pubTimestamp":1774451897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ALPHAMAB-B (09966) announced its annual results for the period ending December 31, 2025. The company recorded revenue of RMB 566 million, representing a decrease of 11.54% compared to the previous...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CYB":"人民币ETF-WisdomTree Dreyfus","BK1161":"生物科技","BK1574":"生物医药B类股","09966":"康宁杰瑞制药-B"},"translate_title":"康宁杰瑞-B年报亏损1.14亿同比扭亏为盈","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYB":1,"CNHmain":1,"UCmain":1,"09966":1,"MUCmain":1,"MCNHmain":1},"content_text":"ALPHAMAB-B (09966) announced its annual results for the period ending December 31, 2025. The company recorded revenue of RMB 566 million, representing a decrease of 11.54% compared to the previous year. It reported an annual loss of RMB 114 million, a shift from profit to loss year-on-year. The loss per share was RMB 0.12. According to the announcement, research and development expenses increased from RMB 404 million for the year ended December 31, 2024, to RMB 572 million for the year ended December 31, 2025. This increase was primarily attributable to (i) a rise in the number of ongoing clinical trials; (ii) the expansion of the scale of the company's clinical studies; and (iii) progress in clinical trials for the company's drug candidates. A detailed breakdown of R&D expenses by nature for the indicated years is provided in the table below.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}